Source: Healio News
Once weekly oral selinexor combined with pomalidomide and dexamethasone was well-tolerated in patients with heavily pretreated multiple myeloma, according to data from the multi-arm phase 1b/2 STOMP study presented at the virtual ASCO Annual Meeting.
When patients received the recommended phase 2 dose, the overall response rate was about 60% and one-third of patients achieved very good partial response, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.
“The reason why it’s interesting is because, as you can